These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 38001037)

  • 21. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.
    Nkinda L; Barabona G; Ngare I; Nkuwi E; Kamori D; Msafiri F; Kunambi PP; Osati E; Kidenya BR; Chuwa H; Kinasa G; Hassan FE; Judicate GP; Gasper J; Kisuse J; Mfinanga S; Senkoro M; Ueno T; Lyamuya E; Balandya E
    J Med Virol; 2024 Aug; 96(8):e29822. PubMed ID: 39056238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
    Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023.
    Poukka E; Perälä J; Nohynek H; Goebeler S; Auranen K; Leino T; Baum U
    Euro Surveill; 2024 Sep; 29(37):. PubMed ID: 39268649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
    Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G
    Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study.
    Grewal R; Kitchen SA; Nguyen L; Buchan SA; Wilson SE; Costa AP; Kwong JC
    BMJ; 2022 Jul; 378():e071502. PubMed ID: 35793826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods.
    Ciesla AA; Wiegand RE; Smith ZR; Britton A; Fleming-Dutra KE; Miller J; Accorsi EK; Verani JR; Shang N; Derado G; Pilishvili T; Link-Gelles R
    Open Forum Infect Dis; 2023 May; 10(5):ofad187. PubMed ID: 37213428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Feb; 11(2):176-187. PubMed ID: 36216013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
    Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
    JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.
    Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Gilca R; Ouakki M; Barkati S; Fafard J; Talbot D; Gilca V; Deceuninck G; Garenc C; Carignan A; De Wals P; De Serres G
    JAMA Netw Open; 2022 Oct; 5(10):e2236670. PubMed ID: 36239934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.
    Hyun H; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak W; Lee JW; Kim B; Song JY
    Front Immunol; 2024; 15():1385135. PubMed ID: 38756783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hybrid immunity from severe acute respiratory syndrome coronavirus 2 infection and vaccination in Canadian adults: A cohort study.
    Brown PE; Fu SH; Newcombe L; Tang X; Nagelkerke N; Birnboim HC; Bansal A; Colwill K; Mailhot G; Delgado-Brand M; Tursun T; Qi F; Gingras AC; Slutsky AS; Pasic MD; Companion J; Bogoch II; Morawski E; Lam T; Reid A; Jha P;
    Elife; 2024 Jun; 13():. PubMed ID: 38916134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.
    Sane Schepisi M
    Epidemiol Prev; 2023; 47(6):331-343. PubMed ID: 38314543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
    Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    Kirsebom FCM; Stowe J; Lopez Bernal J; Allen A; Andrews N
    J Infect; 2024 Jul; 89(1):106177. PubMed ID: 38719110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.
    Bozio CH; Butterfield KA; Briggs Hagen M; Grannis S; Drawz P; Hartmann E; Ong TC; Fireman B; Natarajan K; Dascomb K; Gaglani M; DeSilva MB; Yang DH; Midgley CM; Dixon BE; Naleway AL; Grisel N; Liao IC; Reese SE; Fadel WF; Irving SA; Lewis N; Arndorfer J; Murthy K; Riddles J; Valvi NR; Mamawala M; Embi PJ; Thompson MG; Stenehjem E
    J Infect Dis; 2023 Jun; 227(12):1348-1363. PubMed ID: 36806690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
    Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
    Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.